Literature DB >> 24566001

Focal changes in diffusivity on apparent diffusion coefficient MR imaging and amino acid uptake on PET do not colocalize in nonenhancing low-grade gliomas.

Verena Rahm1, Larissa Boxheimer, Matthias Bruehlmeier, Jatta Berberat, Egbert U Nitzsche, Luca Remonda, Ulrich Roelcke.   

Abstract

UNLABELLED: Low-grade gliomas (LGGs) may harbor malignant foci, which are characterized by increased tumor cellularity and angiogenesis. We used diffusion-weighted MR imaging (apparent diffusion coefficient [ADC]) and PET with the amino acid O-(2-(18)F-fluorethyl)-L-tyrosine ((18)F-FET) to search for focal changes of diffusion (ADC) and amino acid uptake and to investigate whether focal changes in these parameters colocalize within LGGs.
METHODS: We retrospectively selected 18 patients with nonenhancing LGG. All patients had undergone (18)F-FET PET and MR imaging for preoperative evaluation or for therapy monitoring in recurrent or progressive LGG. Region-of-interest analysis was performed to compare (18)F-FET uptake and ADC values in areas with focal intratumoral maximum metabolic activity and diffusion restriction and between tumor and normal brain. (18)F-FET uptake was normalized to the mean cerebellar uptake (ratio). ADC values were also compared with the (18)F-FET uptake on a voxel-by-voxel basis across the whole tumor.
RESULTS: The mean focal maximum (mean ± SD, 1.69 ± 0.85) and global (18)F-FET uptake in tumors (1.14 ± 0.41) exceeded that of normal cortex (0.85 ± 0.09) and cerebrospinal fluid (0.82 ± 0.20). ADC values in the area with most restricted diffusion (1.07 ± 0.22 × 10(-3) mm(2)/s) and in the whole tumor (1.38 ± 0.27 × 10(-3) mm(2)/s) were in the range between normal cortex (0.73 ± 0.06 × 10(-3) mm(2)/s) and cerebrospinal fluid (2.84 ± 0.09 × 10(-3) mm(2)/s). (18)F-FET uptake did not correlate with corresponding (colocalizing) ADC values, either in the area with focal maximum metabolic activity or in the area with most restricted diffusion or in the whole tumor.
CONCLUSION: There is no congruency between (18)F-FET uptake and diffusivity in nonenhancing LGG. Diffusion restriction in these tumors most likely represents changes in brain and tumor cell densities as well as alteration of water distribution and is probably not directly correlated with the density of tumor cells.

Entities:  

Keywords:  MRI; PET; amino acid uptake; diffusion-weighted imaging; low-grade glioma

Mesh:

Substances:

Year:  2014        PMID: 24566001     DOI: 10.2967/jnumed.113.130732

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

1.  Combined FET PET/ADC mapping: improved imaging of glioma infiltration?

Authors:  Karl-Josef Langen; Norbert Galldiks; Philipp Lohmann
Journal:  Neuro Oncol       Date:  2020-03-05       Impact factor: 12.300

2.  ¹⁸F-Fluorocholine PET/CT as a complementary tool in the follow-up of low-grade glioma: diagnostic accuracy and clinical utility.

Authors:  Manuel Gómez-Río; Nathalie Testart Dardel; Alicia Santiago Chinchilla; Antonio Rodríguez-Fernández; Gonzalo Olivares Granados; Raquel Luque Caro; Mercedes Zurita Herrera; Clara E Chamorro Santos; Pablo Lardelli-Claret; José M Llamas-Elvira
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-12       Impact factor: 9.236

3.  Multiparametric evaluation of low grade gliomas at follow-up: comparison between diffusion and perfusion MR with (18)F-FDOPA PET.

Authors:  Maria C Rossi Espagnet; Andrea Romano; Valeria Mancuso; Francesco Cicone; Antonio Napolitano; Claudia Scaringi; Giuseppe Minniti; Alessandro Bozzao
Journal:  Br J Radiol       Date:  2016-08-09       Impact factor: 3.039

4.  Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET.

Authors:  Francesco Cicone; Luciano Carideo; Claudia Scaringi; Andrea Romano; Marcelo Mamede; Annalisa Papa; Anna Tofani; Giuseppe Lucio Cascini; Alessandro Bozzao; Francesco Scopinaro; Giuseppe Minniti
Journal:  Neuro Oncol       Date:  2021-06-01       Impact factor: 12.300

Review 5.  Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective.

Authors:  Lisbeth Marner; Otto M Henriksen; Michael Lundemann; Vibeke Andrée Larsen; Ian Law
Journal:  Clin Transl Imaging       Date:  2016-11-18

Review 6.  Advancements in Neuroimaging to Unravel Biological and Molecular Features of Brain Tumors.

Authors:  Francesco Sanvito; Antonella Castellano; Andrea Falini
Journal:  Cancers (Basel)       Date:  2021-01-23       Impact factor: 6.639

7.  Multi-modal imaging of tumor cellularity and Tryptophan metabolism in human Gliomas.

Authors:  Jeong-Won Jeong; Csaba Juhász; Sandeep Mittal; Edit Bosnyák; David O Kamson; Geoffrey R Barger; Natasha L Robinette; William J Kupsky; Diane C Chugani
Journal:  Cancer Imaging       Date:  2015-08-06       Impact factor: 3.909

Review 8.  Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors.

Authors:  Ji Hoon Jung; Byeong Cheol Ahn
Journal:  Brain Tumor Res Treat       Date:  2018-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.